Gottlieb outlines plans to modernize cancer drug development, review

At the American Society of Clinical Oncology (ASCO) meeting on Saturday, FDA Commissioner Scott Gottlieb highlighted steps the agency is taking to speed cancer drug development and review, including a pilot review program for supplemental efficacy applications, new guidance to relax enrollment criteria in

Read the full 444 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE